Wall Street brokerages expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will post ($0.08) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.11). Catalyst Pharmaceuticals posted earnings of ($0.05) per share during the same quarter last year, which indicates a negative year over year growth rate of 60%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.38) to ($0.24). For the next financial year, analysts expect that the firm will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.35) to ($0.07). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02.
A number of equities analysts have issued reports on CPRX shares. BidaskClub lowered Catalyst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. HC Wainwright set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research report on Monday, August 13th. ValuEngine raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Finally, Oppenheimer started coverage on Catalyst Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $5.21.
Catalyst Pharmaceuticals stock opened at $3.24 on Friday. Catalyst Pharmaceuticals has a one year low of $2.18 and a one year high of $4.51. The company has a market cap of $348.84 million, a P/E ratio of -15.43 and a beta of 1.70.
Several hedge funds have recently bought and sold shares of CPRX. Lido Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $142,000. MetLife Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $157,000. New York State Common Retirement Fund raised its position in shares of Catalyst Pharmaceuticals by 47.6% during the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 24,200 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $230,000. Finally, Rhumbline Advisers raised its position in shares of Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 23,383 shares in the last quarter. 51.49% of the stock is currently owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Further Reading: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.